EGFR and non-small cell lung carcinoma: The treatment landscape for advanced non-small cell lung cancer (NSCLC) has evolved substantially, especially with the introduction of targeted therapies such as osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI).